Reirradiation With Cetuximab in Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck: Feasibility and First Efficacy Results

Department of Radiation Therapy and Oncology, Goethe University, Frankfurt am Main, Germany.
International journal of radiation oncology, biology, physics (Impact Factor: 4.26). 03/2012; 83(3):e377-83. DOI: 10.1016/j.ijrobp.2011.12.088
Source: PubMed


To report our experience with a prospective protocol of external beam reirradiation (Re-RT) combined with cetuximab for patients with inoperable, recurrent squamous cell carcinoma of the head and neck (SCCHN).
Between August 2008 and June 2010, 18 patients with inoperable recurrence of SCCHN after adjuvant or definitive radiotherapy (RT) and simultaneous or sequential cisplatin-based chemotherapy for primary SCCHN were enrolled. Acute and late toxicity from the experimental regimen were recorded every week during RT and every 3 months thereafter. Efficacy was assessed with repeated imaging using response evaluation criteria in solid tumors and clinical examinations 8-12 weeks after completion of the treatment and every 3 months thereafter.
Median follow-up time for all patients was 9.4 (range: 3.85-31.7) months and for patients alive 30.4 (range: 15.7-31.7) months. Acute toxicity was generally mild or moderate. Five patients developed a grade 3 acneiform rash related to cetuximab. Late toxicity occurred as grade 3 trismus in five and as grade 3 abacterial salivary gland inflammation in one patient, respectively. Overall response rate was 47%. Median overall and progression-free survival for all patients was 8.38 months and 7.33 months, respectively. The overall survival rate was 44% at 1 year, with a 1 year local control rate of 33%.
Notwithstanding the limitations of our preliminary data Re-RT combined with cetuximab for recurrent and inoperable SCCHN is feasible and the integration of newer targeted agents seems to be less toxic compared to conventional chemotherapy with encouraging response rates at least for a subset of patients.

15 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The management of head and neck squamous cell carcinomas does not end with the completion of ablative therapy. The oncologic objectives of post-treatment follow-up are to detect recurrences and second primary tumors; beyond that, follow-up should evaluate acute and chronic treatment-related side effects, guide the rehabilitation process, alleviate functional loss, manage pain, restore nutritional status and assess psychosocial factors. In this structured review, we address the questions of timing and the tools required to achieve a complete and coherent routine surveillance. Several guidelines and consensus statements recommend clinical examination as the cornerstone of follow-up which should be performed for at least 5 years, although there are no data in favor of any one particular follow-up program, and only low-level evidence suggests an improvement in oncologic outcomes by close follow-up. Baseline imaging (computed tomography and magnetic resonance imaging) should be obtained within 2-6 months after definitive therapy if used for treatment response evaluation. Metabolic response, if indicated, should be assessed preferably after 3 months in patients who undergo curative-intent therapy with (chemo)-radiotherapy. Chest computed tomography is more sensitive than plain radiography, if used in follow-up, but the benefit and cost-effectiveness of routine chest computed tomography has not been demonstrated. There are no current data supporting modifications specific to the surveillance plan of patients with human papillomavirus-associated disease.
    Archives of Oto-Rhino-Laryngology 09/2012; 270(5). DOI:10.1007/s00405-012-2172-7 · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cetuximab, an anti-epidermal growth factor receptor(EGFR)monoclonal antibody, has been shown to have greater survival benefits as an adjunct to radiotherapy for locally advanced squamous cell carcinoma of the head and neck(LA-SCCHN)as well as a combination with platinum-based chemotherapy for recurrent/metastatic SCCHN(R/M-SCCHN). Based on this conclusive evidence from phaseII/III studies, its use for these indications has been approved in many countries and is recommended by the NCCN guideline 2012. Several other drugs in the same class, including panitumumab and nimotuzumab, are now under development for the treatment of SCCHN. Anti-EGFR monoclonal antibodies are known to cause adverse reactions typically associated with EGFR blockade, against which effective countermeasures have been developed. How to identify likely responders and how to overcome resistance to anti-EGFR monoclonal antibodies are two important challenges for the future.
    Gan to kagaku ryoho. Cancer & chemotherapy 12/2012; 39(13):2489-507.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A multitude of surgical and non-surgical therapies are available to treat malignant epithelial tumors of the skin. The article summarizes the current treatment options for basal cell carcinoma, squamous cell carcinoma and keratoacanthoma. Moreover, the possibilities of primary and secondary prevention for high-risk patients are reviewed. The decision about the best therapeutic option depends on location, age, and general health of the patient as well as the risk of tumor recurrence. Journal compilation
    Journal der Deutschen Dermatologischen Gesellschaft 01/2013; 11(1):9-27. DOI:10.1111/ddg.12001 · 2.05 Impact Factor
Show more